Ken Griffin’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ken Griffin’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,096	Closed	-$177K	–	16111
2022 Q4	$177K	Sell	200,096 -1,348,958	-87%	-$1.79M	﹤0.01%	10353
2022 Q3	$2.43M	Buy	1,549,054 +884,632	+133%	+$2.01M	﹤0.01%	5215
2022 Q2	$1.33M	Sell	664,422 -1,029,400	-61%	-$1.78M	﹤0.01%	6381
2022 Q1	$3.95M	Buy	1,693,822 +691,099	+69%	+$2.16M	﹤0.01%	4640
2021 Q4	$4.66M	Buy	1,002,723 +774,668	+340%	+$4.81M	﹤0.01%	4431
2021 Q3	$1.74M	Buy	228,055 +154,832	+211%	+$1.31M	﹤0.01%	6723
2021 Q2	$710K	Sell	73,223 -503,355	-87%	-$4.01M	﹤0.01%	9220
2021 Q1	$4.77M	Buy	576,578 +521,598	+949%	+$5.51M	﹤0.01%	4361
2020 Q4	$375K	Sell	54,980 -298	-0.5%	-$2.39K	﹤0.01%	8680
2020 Q3	$616K	Sell	55,278 -364,991	-87%	-$3.34M	﹤0.01%	6917
2020 Q2	$2.64M	Buy	+420,269	New	+$1.61M	﹤0.01%	4085
2019 Q4	–	Sell	-298,565	Closed	-$712K	–	9980
2019 Q3	$639K	Sell	298,565 -62,748	-17%	-$146K	﹤0.01%	6330
2019 Q2	$965K	Buy	361,313 +318,848	+751%	+$1.15M	﹤0.01%	5757
2019 Q1	$202K	Sell	42,465 -218,610	-84%	-$574K	﹤0.01%	8199
2018 Q4	$627K	Buy	261,075 +247,468	+1,819%	+$808K	﹤0.01%	6055
2018 Q3	$60K	Sell	13,607 -64,075	-82%	-$355K	﹤0.01%	8767
2018 Q2	$559K	Buy	77,682 +53,703	+224%	+$365K	﹤0.01%	6187
2018 Q1	$123K	Buy	23,979 +11,393	+91%	+$81.1K	﹤0.01%	7639
2017 Q4	$48K	Sell	12,586 -20,137	-62%	-$52.4K	﹤0.01%	7645
2017 Q3	$56K	Buy	+32,723	New	+$60K	﹤0.01%	7161
2017 Q2	–	Sell	-19,476	Closed	-$77K	–	8254
2017 Q1	$77K	Buy	+19,476	New	+$97.7K	﹤0.01%	6941
2016 Q4	–	Sell	-14,100	Closed	-$109K	–	8033
2016 Q3	$109K	Buy	+14,100	New	+$94.9K	﹤0.01%	6621
2016 Q1	–	Sell	-28,792	Closed	-$251K	–	8300
2015 Q4	$251K	Buy	28,792 +27,431	+2,016%	+$231K	﹤0.01%	5488
2015 Q3	$11K	Sell	1,361 -66,830	-98%	-$1.06M	﹤0.01%	8439
2015 Q2	$1.2M	Sell	68,191 -7,946	-10%	-$102K	﹤0.01%	3729
2015 Q1	$880K	Buy	+76,137	New	+$881K	﹤0.01%	4097

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Ken Griffin's SRNE Position: Q1 2023 in Review

Ken Griffin sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 200,096 shares — an estimated $177K sold.

Ken Griffin first reported a position in SRNE in Q1 2015 and held it in 26 quarters. The position peaked at $4.77M in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Ken Griffin reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Ken Griffin sold 200,096 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $177K.
Ken Griffin first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 26 quarters.
Ken Griffin's Sorrento Therapeutics, Inc. position peaked at $4.77M in Q1 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.